The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors

Christoph A. Ritter, Carlos L. Arteaga

Research output: Contribution to journalReview article

153 Citations (Scopus)

Abstract

The overexpression and aberrant function of the epidermal growth factor receptor (EGFR) and its ligands in several human carcinomas have provided a rationale for targeting this signaling network with novel treatment approaches. The epidermal growth factor receptor-tyrosine kinase (EGFR-TK) is a selective target for inhibiting cancer because it is activated in many tumor cells, yet is strictly controlled in normal cells. The EGFR-TK initiates diverse signal transduction pathways in tumor cells that have a profound effect on their biology. Activation of the EGFR-TK provides signals that drive dysregulated proliferation, invasion and metastasis, angiogenesis, and enhanced cell survival. Therefore, the EGFR-TK is a promising drug target for many types of solid tumors, and its inhibition has potential in both the treatment and prevention of these neoplasias. Based on the structure and function of the EGFR, two antireceptor therapeutic strategies have been developed. The first strategy uses humanized monoclonal antibodies generated against the receptors ligand-binding, extracellular domain. These antibodies block binding of receptor-activiting ligands and, in some cases, can induce receptor endocytosis and downregulation. The second approach uses small molecules that compete with adenosine triphosphate for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas. ZD 1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, Including non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalSeminars in Oncology
Volume30
Issue number1 SUPPL. 1
DOIs
StatePublished - Feb 1 2003

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Ligands
Therapeutics
Signal Transduction
Carcinoma
Antibodies, Monoclonal, Humanized
Endocytosis
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Cell Survival
Phosphotransferases
Down-Regulation
Adenosine Triphosphate
Neoplasm Metastasis
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

The epidermal growth factor receptor-tyrosine kinase : A promising therapeutic target in solid tumors. / Ritter, Christoph A.; Arteaga, Carlos L.

In: Seminars in Oncology, Vol. 30, No. 1 SUPPL. 1, 01.02.2003, p. 3-11.

Research output: Contribution to journalReview article

@article{3230d571ffd74513b853d2fb40c6ec8d,
title = "The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors",
abstract = "The overexpression and aberrant function of the epidermal growth factor receptor (EGFR) and its ligands in several human carcinomas have provided a rationale for targeting this signaling network with novel treatment approaches. The epidermal growth factor receptor-tyrosine kinase (EGFR-TK) is a selective target for inhibiting cancer because it is activated in many tumor cells, yet is strictly controlled in normal cells. The EGFR-TK initiates diverse signal transduction pathways in tumor cells that have a profound effect on their biology. Activation of the EGFR-TK provides signals that drive dysregulated proliferation, invasion and metastasis, angiogenesis, and enhanced cell survival. Therefore, the EGFR-TK is a promising drug target for many types of solid tumors, and its inhibition has potential in both the treatment and prevention of these neoplasias. Based on the structure and function of the EGFR, two antireceptor therapeutic strategies have been developed. The first strategy uses humanized monoclonal antibodies generated against the receptors ligand-binding, extracellular domain. These antibodies block binding of receptor-activiting ligands and, in some cases, can induce receptor endocytosis and downregulation. The second approach uses small molecules that compete with adenosine triphosphate for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas. ZD 1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, Including non-small-cell lung cancer.",
author = "Ritter, {Christoph A.} and Arteaga, {Carlos L.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1053/sonc.2003.50015",
language = "English (US)",
volume = "30",
pages = "3--11",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - The epidermal growth factor receptor-tyrosine kinase

T2 - A promising therapeutic target in solid tumors

AU - Ritter, Christoph A.

AU - Arteaga, Carlos L.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The overexpression and aberrant function of the epidermal growth factor receptor (EGFR) and its ligands in several human carcinomas have provided a rationale for targeting this signaling network with novel treatment approaches. The epidermal growth factor receptor-tyrosine kinase (EGFR-TK) is a selective target for inhibiting cancer because it is activated in many tumor cells, yet is strictly controlled in normal cells. The EGFR-TK initiates diverse signal transduction pathways in tumor cells that have a profound effect on their biology. Activation of the EGFR-TK provides signals that drive dysregulated proliferation, invasion and metastasis, angiogenesis, and enhanced cell survival. Therefore, the EGFR-TK is a promising drug target for many types of solid tumors, and its inhibition has potential in both the treatment and prevention of these neoplasias. Based on the structure and function of the EGFR, two antireceptor therapeutic strategies have been developed. The first strategy uses humanized monoclonal antibodies generated against the receptors ligand-binding, extracellular domain. These antibodies block binding of receptor-activiting ligands and, in some cases, can induce receptor endocytosis and downregulation. The second approach uses small molecules that compete with adenosine triphosphate for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas. ZD 1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, Including non-small-cell lung cancer.

AB - The overexpression and aberrant function of the epidermal growth factor receptor (EGFR) and its ligands in several human carcinomas have provided a rationale for targeting this signaling network with novel treatment approaches. The epidermal growth factor receptor-tyrosine kinase (EGFR-TK) is a selective target for inhibiting cancer because it is activated in many tumor cells, yet is strictly controlled in normal cells. The EGFR-TK initiates diverse signal transduction pathways in tumor cells that have a profound effect on their biology. Activation of the EGFR-TK provides signals that drive dysregulated proliferation, invasion and metastasis, angiogenesis, and enhanced cell survival. Therefore, the EGFR-TK is a promising drug target for many types of solid tumors, and its inhibition has potential in both the treatment and prevention of these neoplasias. Based on the structure and function of the EGFR, two antireceptor therapeutic strategies have been developed. The first strategy uses humanized monoclonal antibodies generated against the receptors ligand-binding, extracellular domain. These antibodies block binding of receptor-activiting ligands and, in some cases, can induce receptor endocytosis and downregulation. The second approach uses small molecules that compete with adenosine triphosphate for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas. ZD 1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is the EGFR-TK inhibitor furthest along in clinical development, and it is currently being investigated in a variety of solid tumors, Including non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037296357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037296357&partnerID=8YFLogxK

U2 - 10.1053/sonc.2003.50015

DO - 10.1053/sonc.2003.50015

M3 - Review article

C2 - 12644979

AN - SCOPUS:0037296357

VL - 30

SP - 3

EP - 11

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -